Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study.

MLA

Ji, Dongmei, et al. “Liposomal Irinotecan (HR070803) in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Solid Tumors: A Phase 1b Dose-Escalation and Expansion Study.” Investigational New Drugs, vol. 42, no. 4, Aug. 2024, pp. 462–70. EBSCOhost, https://doi.org/10.1007/s10637-024-01442-2.

APA

Ji, D., Shen, W., Li, T., Wang, H., Bai, J., Cao, J., & Hu, X. (2024). Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study. Investigational New Drugs, 42(4), 462–470. https://doi.org/10.1007/s10637-024-01442-2

Chicago

Ji, Dongmei, Weina Shen, Ting Li, Huan Wang, Jianling Bai, Junning Cao, and Xichun Hu. 2024. “Liposomal Irinotecan (HR070803) in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Solid Tumors: A Phase 1b Dose-Escalation and Expansion Study.” Investigational New Drugs 42 (4): 462–70. doi:10.1007/s10637-024-01442-2.